Eli Lilly launches cancer drug Tanstrive in India

The launch follows marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for patients with locally advanced or metastatic solid tumours with a rearranged during transfection (RET) gene, the company said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IZDaN69
via IFTTT

Read More

NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chain

Niti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think tank urges a shift towards high-value segments, emphasizing enhanced industry-academia collaboration for patent commercialization and startup incubation. While India is the 'pharmacy of the world,' it needs to move up the value chain by focusing on deeptech innovation to become a capital for pharma innovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Blf4C3J
via IFTTT

Read More

India's pharma supply chain remains 65 per cent dependent on China for critical inputs: NITI Aayog

India's pharmaceutical sector, despite being the "pharmacy of the world," faces significant reliance on China for raw materials, with nearly 65% of APIs and intermediates sourced from there. NITI Aayog's report highlights supply chain vulnerabilities and calls for moving up the value chain by fostering innovation and industry-academia collaboration. This strategic shift aims to boost high-value product development and capture a larger global market share.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pPlx4t3
via IFTTT

Read More

Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman role

Healthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna, instrumental in Healthium's growth and acquisitions since 2018, will aid in successor selection. Despite record revenue, the medical devices firm saw profits decline recently, facing market competition and a slowdown in the Indian surgical products sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y0Fua5X
via IFTTT

Read More

Stress, poor sleep and processed food are driving heart attacks in young Indians: Ramakanta Panda

Young Indian professionals, particularly in IT and finance, are facing a heart disease crisis due to unhealthy lifestyles. Leading cardiac surgeon Dr. Ramakanta Panda highlights chronic stress, poor sleep, processed foods, and sedentary habits as major culprits behind a surge in heart attacks among those in their 30s and 40s.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Fy2aELA
via IFTTT

Read More

Central Drugs Laboratories find 46 drug samples not of standard quality for May

Health officials revealed that in May 2026, 46 drug samples tested by Central Drugs Laboratories and 113 by State Drugs Testing Laboratories were found to be of substandard quality. Additionally, one spurious drug, manufactured by an unauthorized entity using another company's brand, was identified in Assam and is under investigation. These findings highlight ongoing efforts to ensure drug safety and remove substandard products from circulation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/F2gpiGV
via IFTTT

Read More

Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett Company

Aurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic move, expected to conclude by June 2026, will bolster Aurobindo's complex generics and controlled substances portfolio, enhance its US manufacturing capabilities with Lannett's Indiana facility, and is projected to immediately boost earnings per share.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qi42rVf
via IFTTT

Read More